ArticleOveractive Bladder SyndromeNwanodi, Oroma B. MD; Levy, Gil MDAuthor Information Dr. Nwanodi is Women's Health Provider, Myrtle Hilliard Davis Comprehensive Health Centers–Homer G. Philips Health Center, 2425 N. Whittier Street, Saint Louis MO 63113, E-mail: email@example.com; and Dr. Levy is Director, Division of Urogynecology and Reconstructive Pelvic Surgery, Mayanei Hayeshua Medical Center, Bnei Brak, Israel. All faculty and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity. The authors have disclosed that botulinum toxin, duloxetine, clenbuterol, norepinephrine, phenylpropanolamine, electromotive drug administration, hormone therapy, posterior tibial nerve modulation, and pudendal nerve stimulation as discussed in this article have not been approved for treatment of overactive bladder syndrome by the U.S. Food and Drug Administration. Lippincott Continuing Medical Education Institute, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article and complete the quiz and evaluation on the enclosed answer form, answering at least seven of the 10 quiz questions correctly. This activity expires on June 29, 2011. Topics in Obstetrics & Gynecology: June 30th, 2010 - Volume 30 - Issue 12 - p 1-8 doi: 10.1097/01.PGO.0000381313.60163.71 Buy Take the CME Test Metrics © 2010 Lippincott Williams & Wilkins, Inc.